NO20092698L - Inhibitorer av poly(adp-ribose)polymerase - Google Patents

Inhibitorer av poly(adp-ribose)polymerase

Info

Publication number
NO20092698L
NO20092698L NO20092698A NO20092698A NO20092698L NO 20092698 L NO20092698 L NO 20092698L NO 20092698 A NO20092698 A NO 20092698A NO 20092698 A NO20092698 A NO 20092698A NO 20092698 L NO20092698 L NO 20092698L
Authority
NO
Norway
Prior art keywords
adp
ribose
inhibitors
poly
polymerase
Prior art date
Application number
NO20092698A
Other languages
English (en)
Norwegian (no)
Inventor
Gui-Dong Zhu
Jianchun Gong
Vincent L Giranda
Viraj B Gandhi
Thomas D Penning
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39584870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092698(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of NO20092698L publication Critical patent/NO20092698L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/58—1,2-Diazines; Hydrogenated 1,2-diazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Hematology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Agronomy & Crop Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20092698A 2006-12-28 2009-07-17 Inhibitorer av poly(adp-ribose)polymerase NO20092698L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88231706P 2006-12-28 2006-12-28
PCT/US2007/088319 WO2008083027A1 (en) 2006-12-28 2007-12-20 Inhibitors of poly(adp-ribose)polymerase

Publications (1)

Publication Number Publication Date
NO20092698L true NO20092698L (no) 2009-09-28

Family

ID=39584870

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092698A NO20092698L (no) 2006-12-28 2009-07-17 Inhibitorer av poly(adp-ribose)polymerase

Country Status (31)

Country Link
US (1) US20080161280A1 (zh)
EP (2) EP2698062B1 (zh)
JP (2) JP5523837B2 (zh)
KR (2) KR101449436B1 (zh)
CN (2) CN103690542B (zh)
AU (1) AU2007340020B2 (zh)
BR (1) BRPI0722070A2 (zh)
CA (1) CA2672868C (zh)
CO (1) CO6220961A2 (zh)
CR (1) CR10901A (zh)
DK (2) DK2698062T3 (zh)
DO (1) DOP2009000159A (zh)
EC (1) ECSP099530A (zh)
ES (2) ES2548353T3 (zh)
GT (1) GT200900182A (zh)
HK (1) HK1194922A1 (zh)
HR (1) HRP20140115T1 (zh)
HU (1) HUE027641T2 (zh)
MX (2) MX2009007051A (zh)
MY (2) MY190838A (zh)
NO (1) NO20092698L (zh)
NZ (2) NZ577348A (zh)
PL (2) PL2120579T3 (zh)
PT (2) PT2120579E (zh)
RS (1) RS53196B (zh)
RU (1) RU2455286C2 (zh)
SG (2) SG2014013411A (zh)
SI (2) SI2698062T1 (zh)
TW (1) TWI429438B (zh)
UA (1) UA97506C2 (zh)
WO (1) WO2008083027A1 (zh)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
KR20100059950A (ko) * 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
AU2008322676B9 (en) * 2007-11-15 2014-03-27 Msd Italia S.R.L. Pyridazinone derivatives as PARP inhibitors
UY31603A1 (es) * 2008-01-23 2009-08-31 Derivados de ftalazinona
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
KR101754698B1 (ko) 2008-12-19 2017-07-26 센트렉시온 테라퓨틱스 코포레이션 염증, 천식 및 ｃｏｐｄ 치료용 ｃｃｒ2 수용체 길항제로서의 사이클릭 피리미딘-4-카복스아미드
EP2389379A1 (en) * 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
EP2459561A1 (en) 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
EA024397B1 (ru) 2009-12-17 2016-09-30 Сентрекшн Терапьютикс Корпорейшн Новые антагонисты рецептора ccr2 и их применение
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
EP2576542B1 (en) 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
JP2013532703A (ja) * 2010-08-03 2013-08-19 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐａｒｐ−１阻害剤および抗新生物剤を含む治療用組合せ
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
MX2013011932A (es) 2011-04-11 2013-11-01 Abbvie Inc Inhibidores de parp para el tratamiento de cipn.
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
TWI548637B (zh) * 2011-07-26 2016-09-11 江蘇豪森藥業集團有限公司 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用
CA2846187A1 (en) * 2011-08-23 2013-02-28 Endo Pharmaceuticals Inc. Pyrimido-pyridazinone compounds and use thereof
AU2012318874A1 (en) 2011-10-06 2014-05-15 Merck Sharp & Dohme Corp. 1,3-substituted azetidine PDE10 inhibitors
CN103242273B (zh) * 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
RU2527457C2 (ru) * 2012-09-27 2014-08-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Ингибиторы поли(адф-рибозо)полимеразы-1 человека на основе производных урацила
BR112015012425A2 (pt) * 2012-12-31 2017-07-11 Cadila Healthcare Ltd composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
US8937178B2 (en) 2013-03-13 2015-01-20 Flatley Discovery Lab Phthalazinone compounds and methods for the treatment of cystic fibrosis
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
CN106146492A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 杂环并咪唑类化合物、其药物组合物及其制备方法和用途
ES2811098T3 (es) 2015-07-02 2021-03-10 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidin-1-il)(5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2hpirano-2-il) metilamino)pirimidin-4il) metanona
WO2018009622A1 (en) * 2016-07-07 2018-01-11 Bristol-Myers Squibb Company Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
RS60209B1 (sr) 2017-03-20 2020-06-30 Forma Therapeutics Inc Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr)
SG11202007646UA (en) 2018-02-13 2020-09-29 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
US20220031671A1 (en) 2018-09-19 2022-02-03 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
WO2021005081A1 (de) * 2019-07-10 2021-01-14 Bayer Aktiengesellschaft Verfahren zur herstellung von 2-(phenylimino)-1,3-thiazolidin-4-onen
MX2022013304A (es) 2020-04-21 2022-12-15 Idience Co Ltd Formas cristalinas de compuesto de ftalazinona.
JP2023529867A (ja) 2020-06-05 2023-07-12 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤
US20220117961A1 (en) * 2020-10-16 2022-04-21 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
WO2022159745A1 (en) * 2021-01-22 2022-07-28 Hibercell, Inc. Gcn2 modulating compounds and uses thereof
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
EP4362978A1 (en) * 2021-06-28 2024-05-08 Merck Sharp & Dohme LLC Il4i1 inhibitors and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0026505D0 (en) * 2000-10-30 2000-12-13 Kudos Pharm Ltd Phthalazinone derivatives
AU2002331621B2 (en) * 2001-08-15 2008-06-05 Icos Corporation 2H-phthalazin-1-ones and methods for use thereof
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
EP1477175B1 (en) * 2002-02-19 2011-04-27 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
ATE491703T1 (de) * 2002-04-30 2011-01-15 Kudos Pharm Ltd Phthalazinonderivate
CA2493234A1 (en) * 2002-07-24 2004-01-29 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2006003147A1 (en) * 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
TWI404716B (zh) * 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
ES2341813T3 (es) * 2006-12-20 2010-06-28 Glaxo Group Limited 4-bencil-1 (2h)-ftalazinonas como antagonistas del receptor h1.
AU2008240679A1 (en) * 2007-04-23 2008-10-30 Novartis Ag Phthalazine and isoquinoline derivatives with SLP receptor modulating activities
KR20100059950A (ko) * 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
ATE525370T1 (de) * 2007-10-11 2011-10-15 Glaxo Group Ltd Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten

Also Published As

Publication number Publication date
EP2120579A1 (en) 2009-11-25
WO2008083027A1 (en) 2008-07-10
KR101449436B1 (ko) 2014-10-14
CN103690542B (zh) 2015-11-18
US20080161280A1 (en) 2008-07-03
EP2698062A1 (en) 2014-02-19
JP5523837B2 (ja) 2014-06-18
KR20090094116A (ko) 2009-09-03
GT200900182A (es) 2010-02-19
CN103690542A (zh) 2014-04-02
SG193664A1 (en) 2013-10-30
PT2698062E (pt) 2015-10-19
DK2698062T3 (en) 2015-09-14
CA2672868A1 (en) 2008-07-10
UA97506C2 (en) 2012-02-27
CO6220961A2 (es) 2010-11-19
AU2007340020B2 (en) 2013-06-20
EP2120579A4 (en) 2011-04-27
JP2010514785A (ja) 2010-05-06
ECSP099530A (es) 2009-08-28
HK1194922A1 (zh) 2014-10-31
DK2120579T3 (da) 2014-02-03
TWI429438B (zh) 2014-03-11
DOP2009000159A (es) 2015-11-30
HUE027641T2 (en) 2016-11-28
PL2120579T3 (pl) 2014-04-30
MY190838A (en) 2022-05-12
EP2120579B1 (en) 2013-11-13
HRP20140115T1 (hr) 2014-03-14
EP2698062B1 (en) 2015-06-24
ES2442496T3 (es) 2014-02-11
AU2007340020A1 (en) 2008-07-10
MX2009007051A (es) 2009-07-10
CR10901A (es) 2009-07-23
BRPI0722070A2 (pt) 2014-04-08
CN101641014B (zh) 2013-12-18
MX347085B (es) 2017-04-06
PT2120579E (pt) 2014-02-17
NZ577348A (en) 2012-04-27
SG2014013411A (en) 2014-07-30
SI2698062T1 (sl) 2015-12-31
TW200840579A (en) 2008-10-16
RU2009128984A (ru) 2011-02-10
CA2672868C (en) 2015-11-24
RU2455286C2 (ru) 2012-07-10
NZ598352A (en) 2013-08-30
KR20140056395A (ko) 2014-05-09
RS53196B (en) 2014-06-30
CN101641014A (zh) 2010-02-03
ES2548353T3 (es) 2015-10-15
SI2120579T1 (sl) 2014-03-31
MY165570A (en) 2018-04-05
PL2698062T3 (pl) 2015-12-31
KR101491998B1 (ko) 2015-02-10
JP2014001209A (ja) 2014-01-09

Similar Documents

Publication Publication Date Title
NO20092698L (no) Inhibitorer av poly(adp-ribose)polymerase
WO2008082887A3 (en) Inhibitors of poly(adp-ribose)polymerase
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
WO2009012280A3 (en) Benzimidazole poly(adp-ribose)polymerase inhibitors
NO20080075L (no) Sammensetninger og fremgangsmater for inhibering av JAK-nervefiberkjeden
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2007024971A3 (en) Hedgehog pathway antagonists to treat disease
NO20084712L (no) Nye farmasoytiske forbindelser
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
NO20092569L (no) Inhibitorer av Akt-aktivitet
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
NO20081454L (no) Met-kinaseinhibitorer
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2008033858A3 (en) Kinase inhibitors, and methods of using and identifying kinase inhibitors
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
WO2007092622A3 (en) Compositions and methods for treating bone
WO2008030505A8 (en) Methods and compositions for the treatment of antibody mediated neuropathies
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
WO2010017541A3 (en) Compositions and methods for treatment of neurodegenerative disease
NO20090608L (no) Tyrosinkinaseinhibitorer
WO2010059004A3 (ko) 스네일-p53 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE INC., US

FC2A Withdrawal, rejection or dismissal of laid open patent application